Institution
University of Saskatchewan
Education•Saskatoon, Saskatchewan, Canada•
About: University of Saskatchewan is a education organization based out in Saskatoon, Saskatchewan, Canada. It is known for research contribution in the topics: Population & Health care. The organization has 25021 authors who have published 52579 publications receiving 1483049 citations. The organization is also known as: USask.
Papers published on a yearly basis
Papers
More filters
TL;DR: Compared with controls, basal peroxidation is significantly higher in Alzheimer's cortex, and this difference is also evident in the presence of exogenous iron.
Abstract: The formation of thiobarbituric acid-reactive products was measured as an index of peroxidation by oxygen free radicals in homogenates of frontal cortex and cerebellum from brains taken at autopsy and verified histologically as being Alzheimer's (n = 6) or normal (n = 6). Compared with controls, basal peroxidation is significantly higher in Alzheimer's cortex, and this difference is also evident in the presence of exogenous iron. Peroxidation in cerebellum and levels of total glutathione, RNA, and DNA in cortex and cerebellum do not differ significantly between Alzheimer's brain and controls. Iron-induced peroxidation in cortex is reduced by the lazaroid U-74500A, with calculated IC50 values that are significantly higher in Alzheimer's samples (10 microM) than in controls (2.5 microM). These observations suggest that cerebral cortex from Alzheimer's patients differs from controls with respect to in vitro peroxidation.
467 citations
TL;DR: By measuring dopamine receptors in the putamen and caudate of postmortem brains from Parkinson patients, evidence is reported in support of the theory of dopaminergic supersensitivity in Parkinson's disease.
Abstract: IN patients with Parkinson's disease, the concentration of dopamine in the basal ganglia of the brain is markedly reduced in accordance with the degeneration of the nigrostriatal dopamine-containing neurones1,2. This fact provided the basis for the successful clinical introduction of L-dopa (L-3,4-dihydroxyphenylalaline) for Parkinson's disease3,6. It has been suggested that one of the critical factors compensating for the loss of dopamine neurones may be the development of “denervation supersensitivity” in the striatum, as severe cases react more sensitively to L-dopa than milder cases or controls7–9. By measuring dopamine receptors in the putamen and caudate of postmortem brains from Parkinson patients, we report here evidence in support of the theory of dopaminergic supersensitivity in Parkinson's disease.
466 citations
TL;DR: Data support a model in which a metacognitive judgment about a first, initial model determines the extent of analytic engagement, and were consistently predicted by the fluency with which the initial answer was produced, providing a link to the wider literature on metamemory.
466 citations
University of Calgary1, McGill University Health Centre2, Cardiovascular Institute of the South3, University of British Columbia4, Université du Québec à Trois-Rivières5, Université de Montréal6, Laval University7, McMaster University8, Alberta Health Services9, University of Alberta10, McGill University11, University of Toronto12, Heart and Stroke Foundation of Canada13, Population Health Research Institute14, Montreal General Hospital15, University of Western Ontario16, Montreal Heart Institute17, Winnipeg Regional Health Authority18, Université du Québec à Montréal19, Northern Ontario School of Medicine20, St. Michael's Hospital21, University of Manitoba22, Centre for Addiction and Mental Health23, University of Ottawa24, University Health Network25, Concordia University Wisconsin26, Ottawa Hospital Research Institute27, University of Ontario Institute of Technology28, Hôpital Maisonneuve-Rosemont29, University of Saskatchewan30, Centre Hospitalier Universitaire Sainte-Justine31, Children's Hospital of Eastern Ontario32, St Thomas' Hospital33, Mount Sinai Hospital, Toronto34, Université de Sherbrooke35, Brown University36, Concordia Hospital37, University of Pennsylvania38
TL;DR: All individuals with hypertension should have an assessment of global cardiovascular risk to promote health behaviours that lower blood pressure, and an angiotensin receptor-neprilysin inhibitor combination should be used in place of either an ang Elliotensin-converting enzyme inhibitor or angiotENSin receptor blocker in individuals with heart failure.
465 citations
University of Alberta1, Montreal Heart Institute2, University Health Network3, McGill University4, McMaster University5, University of Waterloo6, University of Calgary7, Université de Sherbrooke8, University of Western Ontario9, St. Michael's Hospital10, Halifax11, Royal Jubilee Hospital12, University of British Columbia13, St. Boniface General Hospital14, Sunnybrook Health Sciences Centre15, University of Saskatchewan16, Durham University17, Laval University18, University of Colorado Boulder19, Université de Montréal20, St. John's University21
TL;DR: The 2017 HF guidelines provide updated guidance on the diagnosis and management that should aid in day-to-day decisions for caring for patients with HF, with attention to strategies and treatments to prevent HF, to the organization of HF care, comorbidity management, as well as practical issues around the timing of referral and follow-up care.
465 citations
Authors
Showing all 25277 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Tomas Hökfelt | 158 | 1033 | 95979 |
| Frederick Wolfe | 119 | 417 | 101272 |
| Christopher G. Goetz | 116 | 651 | 59510 |
| John P. Giesy | 114 | 1162 | 62790 |
| Helmut Kettenmann | 104 | 380 | 40211 |
| Paul M. O'Byrne | 104 | 605 | 56520 |
| Susan S. Taylor | 104 | 518 | 42108 |
| Keith A. Hobson | 103 | 653 | 41300 |
| Mark S. Tremblay | 100 | 541 | 43843 |
| James F. Fries | 100 | 369 | 83589 |
| Gordon McKay | 97 | 661 | 61390 |
| Jonathan D. Adachi | 96 | 589 | 31641 |
| Wenjun Zhang | 96 | 976 | 38530 |
| William C. Dement | 96 | 340 | 43014 |
| Chris Ryan | 95 | 971 | 34388 |